Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / NVO

Stock rating

Novo-Nordisk A/S (NVO) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Novo-Nordisk A/S 60 out of 100 (Hold). Its highest factor score is business quality at 95, and its lowest is price momentum at 29.

MELANY ratingRated 2026-11-20

NVO · composite score

60/100
Hold
Nov 20
Rating date
Live price in the app →
Quality95
Momentum29
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About Novo-Nordisk A/S

Novo Nordisk, headquartered in Denmark, is the world's leading provider of diabetes care products and holds roughly one-third of the global branded diabetes treatment market. It develops and sells human and modern insulins, injectable diabetes therapies including GLP-1 treatments, oral antidiabetic agents, and obesity treatments, plus a biopharmaceutical segment (under 10% of revenue) focused on protein therapies for hemophilia and other disorders.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why NVO scores 60/100

NVO's 8 factor scores run from 29 to 95, and 4 of them sit above its composite of 60. Here is how NVO breaks down.

Valuation65/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • P/E 9.5x vs sector 22.0x median
Business quality95/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 81%
  • ROE 59%
Price momentum29/100

Direction and relative strength of the recent share-price trend.

Earnings track record56/100

History of beating or missing estimates, and where estimates are heading.

Analyst sentiment64/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How NVO compares

As of November 20, 2026, Novo-Nordisk A/S is tied for 6th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

All stock rating pages.

Key risks for NVO

  • Weak price momentum, trend not yet confirmed, may need more time to set up
  • Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt

Sector and theme context

Novo-Nordisk A/S sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 97/100 for strength. Theme strength feeds NVO's momentum and catalyst factors above.

Tracking NVO

Novo-Nordisk A/S rates Hold right now, so MELANY is not flagging a fresh entry. Add NVO to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.

How MELANY rates NVO

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Novo-Nordisk A/S's 60/100 reflects mature factor weighting for its profile.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about NVO

Is Novo-Nordisk A/S (NVO) a buy?

As of 2026-11-20, MELANY rated Novo-Nordisk A/S Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does NVO rank against similar companies?

As of November 20, 2026, Novo-Nordisk A/S is tied for 6th of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).

Should I buy Novo-Nordisk A/S stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Novo-Nordisk A/S (NVO) Hold with a composite of 60/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the NVO stock price forecast?

MELANY does not publish price targets or forecasts for NVO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Novo-Nordisk A/S, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for NVO as of 2026-11-20: its analyst sentiment factor is 64/100, and its price momentum factor is 29/100.

Is NVO stock overvalued or undervalued?

MELANY's valuation factor currently reads 65/100 for Novo-Nordisk A/S, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives NVO's read.

What price should I buy NVO at?

MELANY is not flagging a fresh entry for NVO at its current Hold rating, so there is no entry zone to publish right now. Add NVO to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.

What are the risks of buying NVO stock?

The top risks MELANY currently flags for Novo-Nordisk A/S: Weak price momentum, trend not yet confirmed, may need more time to set up; Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Novo-Nordisk A/S a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 95/100 for Novo-Nordisk A/S, and earnings track record, at 56/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will NVO stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 29/100 for NVO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this NVO rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores NVO as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, NVO included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.